“A novel and potent brain penetrant inhibitor of extracellular vesicle release” Camilo Rojas, Barbara Slusher, et al. 2019 Brit J Pharmacology 176: 3857-70. Doi: 10.1111/bph.14789. Using high throughput screening of 365,000 compounds, this research group from Johns Hopkins identified “PDDC”, a compound which penetrated brain tissue and inhibited release of murine astrocyte-derived EVs. Ancell anti-human […]

Check out the exciting new EVix extracellular vesicle research tools from InCepix.com!

Visit Ancell at the 2019 Autumn Immunology Conference at the Downtown Marriott Hotel in Chicago.  We’ll be exhibiting at booth T3  Sat Nov 23 through Sun Nov 24th . 

Neutrophils enact lysis of antibody opsonized target tumor cells by utilizing the CD11b – CD18 interaction to form a cytotoxic synapse which leads to trogocytosis.  This process can be effectively blocked by blockade with either anti-CD11b or anti-CD18 mAbs, but is enhanced when SIRPa – CD47 blockade is employed. “Neutrophils Kill Antibody Opsonized Cancer Cells

“Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus” Stuart J, Stephen H Clarke, et al.  July 1, 2019 Journal of Immunology 203(1): 58-75.  Doi: htpps://doi.org.10.4049/jimmunol.1900043.   Relevant Ancell Products anti-human CD40 mAb Recombinant human CD40-muIg Recombinant human CD154-muCD8

We’ll be exhibiting at the American Immunology Association meeting in San Diego May 10-13 .  Visit us at booth # 417.   

Visit Ancell at booth 4668 at the American Association for Cancer Research meeting in Atlanta Sunday March 31st – Tuesday April 3.  We are co exhibiting with our friends at Incepix!

Anti-CD47 H5F9-G4 antibody blocks CD47 – SIRPa interaction and has been shown to restore anti-cancer immunity in mouse models.  In recent human studies, initial drug dose showed promising effect and was well tolerated in combination with Rituximab(anti-CD20) with side effects of anemia, headache and fatigue.   Relevant Ancell Products New anti-human CD47 mAb

The authors prove the concept that an anti-TCR Cb1 CAR cell based on the epitope of Jovi-1 anti-TCR Cb1 mAb can kill malignant T cell leukemic cells without destroying TCR Cb2 cells.  ”Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.” Paul M Maciocia, Martin A Pule, et al. (2017)

The authors surmise that the presence or absence of CD62L expression on these cells could be used as a diagnostic indicator of autoimmune diseases, such as Crohn. CD62L Is a Functional and Phenotypic Marker for Circulating Innate Lymphoid Cell Precursors  Yotam E. Bar-Ephraim, Reina E. Mebius et al.  J Immunol January 1, 2019, 202 (1)